| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.OPHTHA.2012.01.028 |
| P8608 | Fatcat ID | release_d3layixnazearopfzzgo2bmi6i |
| P698 | PubMed publication ID | 22525048 |
| P2093 | author name string | Min Zhang | |
| Gary N Foulks | |||
| Kelly K Nichols | |||
| Karen J Klamerus | |||
| Jim Z Li | |||
| Shiao Hui Melissa Liew | |||
| P433 | issue | 7 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| eye disease | Q3041498 | ||
| tofacitinib | Q3530324 | ||
| phase I clinical trial | Q5452194 | ||
| P304 | page(s) | 1328-1335 | |
| P577 | publication date | 2012-04-22 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial | |
| P478 | volume | 119 |
| Q39116873 | A biophysical and computational study unraveling the molecular interaction mechanism of a new Janus kinase inhibitor Tofacitinib with bovine serum albumin |
| Q38148616 | Changing trends in the treatment of dry-eye disease |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q39404635 | Dry Eye Management: Targeting the Ocular Surface Microenvironment. |
| Q26852044 | Dry eye: an inflammatory ocular disease |
| Q47836614 | Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. |
| Q92072381 | Emerging Topical and Systemic JAK Inhibitors in Dermatology |
| Q38102006 | Emerging drugs for the treatment of dry eye disease |
| Q38077992 | Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. |
| Q38984001 | Investigational drugs in dry eye disease |
| Q47439880 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases |
| Q48556502 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. |
| Q26865446 | Janus kinase inhibitors in autoimmune diseases |
| Q34028408 | Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. |
| Q37610134 | Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. |
| Q38261371 | Selective JAK inhibitors |
| Q38171801 | Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. |
| Q39337533 | Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors |
| Q38317993 | The JAK-STAT pathway: impact on human disease and therapeutic intervention |
| Q38219053 | The eye: a window of opportunity in rheumatoid arthritis? |
| Q52721623 | The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. |
| Q26822610 | Therapeutic Strategies to Treat Dry Eye in an Aging Population |
| Q33854992 | Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis |
| Q60308037 | Tofacitinib for refractory uveitis and scleritis |
| Q90093016 | Topical cyclosporine A therapy for dry eye syndrome |
| Q26775111 | Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases |
| Q47100458 | Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review |
Search more.